Ampio Pharmaceuticals Inc.
AMPE
AMPE was delisted on the 12th of April, 2024.
95 hedge funds and large institutions have $1.77M invested in Ampio Pharmaceuticals Inc. in 2022 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 11 increasing their positions, 24 reducing their positions, and 20 closing their positions.
6,100% more call options, than puts
Call options by funds: $62K | Put options by funds: $1K
14% less funds holding
Funds holding: 111 → 95 (-16)
54% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 24
67% less capital invested
Capital invested by funds: $5.41M → $1.77M (-$3.64M)
75% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 20
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$194K |
| 2 |
SA
Shilanski & Associates
Anchorage,
Alaska
|
+$109K |
| 3 |
Millennium Management
New York
|
+$76.7K |
| 4 |
Two Sigma Advisers
New York
|
+$38K |
| 5 |
Man Group
London,
United Kingdom
|
+$21.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
E
Ergoteles
New York
|
-$161K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$77.4K |
| 3 |
Renaissance Technologies
New York
|
-$73K |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$66K |
| 5 |
AAP
Arax Advisory Partners
Denver,
Colorado
|
-$62K |
AMPE Hedge Fund Activity: Q3 2022 in Review
95 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Ampio Pharmaceuticals Inc. (AMPE) for Q3 2022, worth a combined $1.77M — down 67% from $5.41M a quarter earlier.
Sellers outnumbered buyers: 20 funds closed out of AMPE and 5 opened new positions — a net loss of 15 holders — while 24 trimmed existing stakes and 11 added.
The largest buyer was Vanguard Group, adding an estimated $194K. The largest seller was Ergoteles, exiting entirely with an estimated $161K sold.
- 95 institutional investors held Ampio Pharmaceuticals Inc. (AMPE) as of Q3 2022, down from 111 in Q2 2022.
- Funds reported $1.77M of Ampio Pharmaceuticals Inc. stock for Q3 2022, down 67% quarter-over-quarter.
- 5 funds opened new Ampio Pharmaceuticals Inc. positions in Q3 2022 and 20 closed out, a net change of -15 holders.
- The largest Ampio Pharmaceuticals Inc. buyer in Q3 2022 was Vanguard Group, an estimated $194K added.
- The largest Ampio Pharmaceuticals Inc. seller in Q3 2022 was Ergoteles, an estimated $161K sold.
Based on aggregated 13F filings for Q3 2022.